Aclaris Therapeutics reported that its first‑in‑human Phase 1a study of the anti‑TSLP/IL‑4Rα bispecific antibody ATI‑052 produced full top‑line results that exceeded the company’s target profile, confirming a highly potent safety and pharmacokinetic profile that supports a potential three‑month dosing interval.
The healthy‑volunteer study showed a favorable safety profile with no serious adverse events, a half‑life of approximately 45 days, and complete inhibition of TSLP‑ and IL‑4‑induced CCL17 (TARC) production at both single and multiple ascending dose levels, indicating dose‑proportional pharmacokinetics and robust pharmacodynamics.
In parallel, Aclaris identified lichen planus as the lead indication for its oral ITK/JAK3 dual inhibitor ATI‑2138, a novel mechanism that targets pathogenic T cells in interface dermatitis disorders. The company plans to initiate a Phase 2b basket study in lichen planus later this year, with the first part focusing on erosive mucosal and cutaneous disease.
Both programs will advance to Phase 1b proof‑of‑concept studies in asthma and atopic dermatitis, with top‑line data expected in the second half of 2026. A Phase 2b program for ATI‑052 in asthma is slated for the fourth quarter of 2026, while ATI‑2138’s Phase 2b study will begin in the second half of 2026.
Aclaris’s financial position supports these milestones: as of December 31 2025, the company held $151.4 million in cash, cash equivalents, and marketable securities, providing runway into the second half of 2028. The lichen planus market opportunity is estimated at $1.0 billion to $4.0 billion in the U.S., underscoring the commercial potential of ATI‑2138.
Analysts have responded positively: Oppenheimer upgraded the stock to “Outperform” and H.C. Wainwright maintained a “Buy” rating, citing the strong clinical data and the high unmet need in both the asthma/atopic dermatitis and lichen planus markets.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.